Aurobindo Pharma is planning to expand into European Union (EU) countries such as Poland and the Czech Republic as part of its broader efforts to consolidate business over the next 3-4 years. The company, which is also eyeing growth in Italy and Spain, is planning to launch various new products in the US market.
Moreover, the Hyderabad-based firm is working on plans to launch cancer treatment and injectable products in the European Union. The acquisition of Generis Farmaceutica SA has already catapulted the company into a big league in the Portuguese generic market in terms of value and volume. It has also completed the acquisition of Orocal brand to leverage its position as a key player in the French drug market.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |